Skip to main content
. 2009 Jan;11(1):96–101. doi: 10.1593/neo.81264

Figure 1.

Figure 1

(A) BODIPY-prazosin uptake assay indicates that HhAntag691 is a potent ABCG2/BCRP inhibitor. HEK293 cells overexpressing ABCG2 were incubated in medium containing 50 µM VP, 5 µM FTC, 20 µM HhAntag691, or no drug, then BODIPY-prazosin was added to a final concentration of 0.25 µM, and incubated at 37°C for 2 hours. Cells were then harvested, and subjected to flow cytometry (excitation wavelength, 488 nm; emission wavelength, 530 nm). Data were analyzed with CellQuest software. (B) HhAntag691 causes a dose-dependent increase of bioluminescence signal in HEK293/ABCG2 cells expressing fLuc. Cells were imaged in medium containing 50 µg/mL D-luciferin and increasing concentrations of HhAntag691, and bioluminescence signal was quantified. Mean ± SEM, n = 3.